Official title: Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Summary: To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide. Conditions: Myeloma Multiple Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE2 Enrollment: 94 (ESTIMATED) Status: RECRUITING Completion: 2027-12-31 (ESTIMATED)
ClinicalTrials.gov published a clinical update in Cardiology on 05 Mar 2026.
The item focuses on Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma.
Review the original article for the full source wording and details.